# Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

> **NCT04938817** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 110 (estimated)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **BIOLOGICAL:** coformulation pembrolizumab/quavonlimab
- **DRUG:** lenvatinib
- **BIOLOGICAL:** MK-4830
- **BIOLOGICAL:** coformulation favezelimab/pembrolizumab
- **BIOLOGICAL:** R-DXd

## Key facts

- **NCT ID:** NCT04938817
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-19
- **Primary completion:** 2029-12-10
- **Final completion:** 2029-12-10
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04938817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04938817, "Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT04938817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*